news

UK approves Janssen COVID-19 Vaccine

1
SHARES

The Janssen COVID-19 Vaccine has been granted conditional marketing authorisation for use in people aged 18 and over in the UK.

doctor wearing face mask holding a vial labelled 'COVID-19 Vaccine'

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Janssen COVID-19 Vaccine conditional marketing authorisation (CMA). The approval allows the single-dose vaccine to be used in Great Britain for protection against COVID-19 in people aged 18 years and older.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Dr June Raine, MHRA Chief Executive, commented: “We have undertaken a thorough review of the conditional marketing authorisation application submitted by Janssen, including the information on quality, safety and effectiveness. I am pleased to confirm today that this authorisation has been granted. This is encouraging news for the public and the healthcare sector. We now have four safe and effective vaccines approved to help protect us from COVID-19.

“Our work does not end here. We are continually monitoring all COVID-19 vaccines in use once they have been approved to ensure that the benefits in protecting people against the disease continue to outweigh any risks. The safety of the public will always come first – you can be absolutely sure of our commitment to this.”

In making the decision the MHRA also obtained independent scientific advice from the Commission on Human Medicines (CHM) and its COVID-19 Expert Working Group.

Professor Sir Munir Pirmohamed, Chair of the independent Commission on Human Medicines, said: “The independent Commission on Human Medicines and its COVID-19 Expert Working Group have carefully considered the MHRA’s evaluation of the application submitted by Janssen and are pleased to say that we have given the vaccine a positive recommendation. This is yet another win for the vaccination programme, which has saved thousands of lives so far.”

The National Institute for Biological Standards and Control, part of the Agency, is carrying out independent batch release on all of the approved COVID-19 vaccines to ensure that every batch meets the expected quality standards and will do so for the Janssen COVID-19 Vaccine.

The Janssen COVID-19 Vaccine was approved for emergency use by the US Food and Drug Administration and the European Commission in March 2021.

Share via
Share via